0
Critical Care |

De-escalation Therapy for Ventilator Associated Pneumonia - Correlation Between Bronchoalveolar Lavage and Clinical Pulmonary Infection Score

Vimala Rapaka, MD; Anmol Kharbanda, MD; Parthiv Desai*, MD; Sindhaghatta Venkatram, MD; Gilda Diaz-Fuentes, MD
Author and Funding Information

Bronx Lebanon Hospital Center, Bronx, NY


Chest. 2012;142(4_MeetingAbstracts):368A. doi:10.1378/chest.1388815
Text Size: A A A
Published online

Abstract

SESSION TYPE: ICU Safety and Improvement Strategies

PRESENTED ON: Tuesday, October 23, 2012 at 02:45 PM - 04:15 PM

PURPOSE: Antibiotic are commonly indicated in Intensive Care unit (ICU) for Ventilator-Associated pneumonia (VAP). A surrogate tool for VAP diagnosis is the Clinical Pulmonary Infection Score (CPIS). Goal of the study was to evaluated role of bronchoscopic bronchoalveolar lavage (BAL) in de-escalation of antibiotics

METHODS: Retrospectively review of ICU patients undergoing BAL for VAP from January 2010 to July 2011. Based in the risk for VAP three groups were identified: low (CPIS≤3), intermediate ( CPIS 4-6) and high-risk ( CPIS>6). Demographics, severity of illness and BAL data were compared between the intermediate and high risk groups. Primary outcome was antibiotic de-escalation; secondary outcomes were: identification of organism, quantitative BAL cultures≥ 104(+QC), ICU length of stay (ICULOS), hospital mortality.

RESULTS: 147 BAL were performed for suspected VAP; 117(80%) patients had intermediate and 28(19%) had high risk for VAP. There was a difference for presence of severe sepsis/septic shock and low albumin levels in high-risk VAP patients (39.4%versus78.5%, p 0.001) and (2.6± 0.69 versus 2.9±0.78, p 0.05) respectively. No differences were found for age, gender, APACHE IV, incidence of nursing home and HIV infected patients; neither for PaO2, PaO2/FiO2, WBC and platelets count, creatinine levels. The high-risk group had more organisms identified (85.7%versus 53.7% p=0.002 and a trend for higher +QC (35.7% versus 27.7%, p 0.48) compared to the intermediate risk-group. Antibiotic de-escalation was done in 100% of intermediate versus 66% of the high risk-group (p 0.47). De-escalation occurred in 90% with identified organism and in all patients with +QC and identified organism. No difference in ICULOS or mortality was found.

CONCLUSIONS: Reported de-escalation of antibiotics in VAP varies from 22-74%. In our study, bronchoscopic BAL resulted in de-escalation in 90% of patients when organism was identified.

CLINICAL IMPLICATIONS: We suggest bronchoscopic BAL for suspected VAP with CPIS≥4 as 27.7% of the intermediate risk patients had +QC which is considered diagnostic of VAP. In high risk-group we recommend use of combined +QC and presence of organism before de-escalation

DISCLOSURE: The following authors have nothing to disclose: Vimala Rapaka, Anmol Kharbanda, Parthiv Desai, Sindhaghatta Venkatram, Gilda Diaz-Fuentes

No Product/Research Disclosure Information

Bronx Lebanon Hospital Center, Bronx, NY

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543